RxSight vs Sanara MedTech
RXST and SMTI side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RXST and SMTI compare
Sanara MedTech is the larger company, worth 1.5 times as much as RxSight ($301M against $201M).
Sanara MedTech grew revenue faster over the last twelve months (13.0% versus −13.2% for RxSight).
Sanara MedTech keeps more of each dollar of sales as profit, with a net margin of −29.2% compared with −36.8% at RxSight.
RxSight scores higher on the StockData Score (10 against 6 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RXST | SMTI |
|---|---|---|
| Size and price | ||
| Market cap | $201M | $301M |
| Share price | $4.83 | $32.73 |
| Change, 1 year | −50.4% | 51.9% |
| Change, 5 years | −61.0% | 14.2% |
| Beta (5Y) | 1.33 | 1.43 |
| Employees | 461 | 108 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.6× (better) | 2.7× |
| P/B | 0.8× (better) | 37.9× |
| EV/EBITDA | – | 30.4× |
| P/FCF | – | 66.8× |
| FCF yield | −13.5% | 1.5% (better) |
| Fair value | $20.39 | $13.42 |
| Margin of safety | 76.3% (better) | −144% |
| Growth | ||
| Revenue growth (TTM) | −13.2% | 13.0% (better) |
| Revenue growth, 5Y average | 55.7% (better) | 45.9% |
| Profitability | ||
| Gross margin | 77.5% | 93.0% (better) |
| Operating margin | −43.2% | 7.7% (better) |
| Net margin | −36.8% | −29.2% (better) |
| FCF margin | −21.3% | 4.1% (better) |
| Return on equity | −17.3% (better) | −148% |
| Return on invested capital | −82.9% | 13.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 5.85 (better) |
| Net debt / EBITDA | – | 2.85 |
| Interest coverage | −3674.3× | 1.2× (better) |
| Current ratio | 4.07 (better) | 2.58 |
| Altman Z-score | −0.70 | 3.76 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | −1.00% | – |
| Shareholder yield | −1.00% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 99.6% | 19.4% |
| Held by insiders | 5.4% | 14.9% |
| Insider net buying, 12 months | −$118K | – |
| Short interest, % of float | 9.2% | 5.3% |
Go deeper
- RXST stock overview
- RXST income statement
- RXST valuation and score
- SMTI stock overview
- SMTI income statement
- SMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.